Improving Sarcoma Care Globally: Access, Equity, Advocacy and Policy

(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.

(P 127) TRENDS IN CONTACTS TO THE SARCOMA UK SUPPORT LINE

(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA

(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE

(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS

(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES

(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.

(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"

(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.

(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY

(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP

(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE

(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)

(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY

(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.

(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA

(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY

(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES

(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS

(P 145) OUTCOMES OF BREAST ANGIOSARCOMA UNDERGOING TREATMENT IN A SPECIALIST CENTRE

(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY

(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE

(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE

(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN

(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT

(P 151) DEVELOPMENT AND IMPACT OF A PRIMARY CARE SARCOMA EDUCATION MODULE FOR ENGLAND AND WALES

(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS

(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS

(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS

(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES

(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP

(P 157) QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES